key: cord-0296535-cnfpsbuk authors: Caspersen, I. H.; Magnus, P.; Trogstad, L. title: Excess risk and clusters of symptoms after COVID-19 in a large Norwegian cohort date: 2021-10-18 journal: nan DOI: 10.1101/2021.10.15.21265038 sha: 3473c64ce2d4763161e8889384c90000081baf5b doc_id: 296535 cord_uid: cnfpsbuk Physical, psychological and cognitive symptoms have been reported as post-acute sequelae for COVID-19 patients but are also common in the general, uninfected population. We aimed to calculate the excess risk and identify patterns of 22 symptoms up to 12 months after COVID-19 infection. We followed more than 70,000 participants in an ongoing cohort study, the Norwegian Mother, Father and Child Cohort Study (MoBa) during the COVID-19 pandemic. Infected and non-infected cohort participants registered presence of 22 different symptoms in March 2021. One year after the initial infection, 13 of 22 symptoms were associated with SARS-CoV-2 infection, based on relative risks between infected and uninfected subjects. For instance, 17.4% of SARS-CoV-2 infected cohort participants reported fatigue that persist 12 months after infection, compared to new occurrence of fatigue that had lasted less than 12 months in 3.8% of non-infected subjects (excess risk 13.6%). The adjusted relative risk for fatigue was 4.8 (95 % CI 3.5 to 6.7). Two main underlying factors explained 50% of the variance in the 13 symptoms. Brain fog, poor memory, dizziness, heart palpitations, and fatigue had high loadings on the first factor, while shortness-of breath and cough had high loadings on the second factor. Lack of taste and smell showed low to moderate correlation to other symptoms. Anxiety, depression and mood swings were not strongly related to COVID-19. Our results suggest that there are clusters of symptoms after COVID-19 due to different mechanisms and question whether it is meaningful to describe long COVID as one syndrome. In light of the many million people infected by SARS-CoV-2, it is important to understand the longterm physical, psychological and cognitive consequences for infected subjects in a population perspective. How common are the symptoms that persist or occur after infection, how long will they last, and what do they consist of? Since reported symptoms are mostly of a general nature, apart from altered smell and taste, one must take account of the incidence of these complaints in the uninfected population. Recent reviews 1-3 of post-acute COVID-19 syndrome or long COVID mostly refer to follow-up studies of patients treated in the specialised health services. These studies are important for detailed understanding of the multi-organ sequelae of COVID-19, but do not represent all infected subjects, do not take account of the incidence of symptoms in the general, uninfected population, and do not subtract symptoms that were present before infection. The reviews show that the design, sampling and outcome measures in follow-up studies are heterogeneous, making meta-analyses difficult [1] [2] [3] . There is a need for population-based, large cohort studies with long-term follow-up that registers new symptoms both in infected and non-infected subjects. We have used the Norwegian Mother, Father and Child Cohort Study (MoBa) 4 , and compare the proportion of new symptoms for participants with and without COVID-19, calculating excess risks for each symptom. We also show the number of symptoms reported by each participant and examine the symptom profile for participants infected 1-6 or 11-12 months ago. We compare risks for men and women, and for subjects with and without severe disease. There is no clear consensus of what constitutes the post-acute COVID-19 syndrome. Since there are symptoms from several organ systems, such as the nervous and respiratory systems, it is of interest to aggregate the long list of symptoms into clusters that can explain as much variation as possible. Using exploratory factor analysis, we have reduced the complexity of symptoms into two factors. 4 ii) a COVID-19 diagnosis in autumn/winter (Wave-2), including those with a diagnosis registered between September 1 st 2020 and January 31 st 2021. The control groups were defined by those who had not received a COVID-19 diagnosis at all during the study period. A questionnaire was distributed to the participants' mobile phones on March 2 nd , 2021. The questionnaire included a list of 22 specific symptoms/signs or diseases (Supplementary Table 1 ). For simplicity, we refer to all listed symptoms/signs/diseases as "symptoms". All participants were asked to check off if they had any of the listed symptoms. The symptoms were selected based on a list from Centres for Disease Control (CDC) in the US 7 . Participants reporting any symptom were also asked about the duration (<1 month, 1-3 months, 4-6 months, 7-12 months, 13-18 months, >18 months). Among COVID-19 cases, we considered symptoms to be novel if the reported duration was shorter than the time since acquiring a COVID-19 diagnosis. Vaccination status was obtained from the Norwegian Immunisation Registry (SYSVAK) 12 . From the existing MoBa database, we included variables on the participants' age (continuous, calculated from birth year), gender (defined by cohort member role as mother or father), and as proxy of socioeconomic status, educational level (less than high school, high school, college ≤4 years, more than 4 years college). Underlying chronic illness were self-reported in three questionnaires to cohort participants distributed in March and April 2020. The following diseases were reported: asthma or other lung disease, cancer, heart disease, hypertension, diabetes, other disease, or no disease. We grouped participants together if they reported at least one disease (including "other disease") in any of the three questionnaires. From the ongoing data collection, we also included information from January 2021 on current smoking (no/yes; and if yes: occasional/daily) and body mass index (BMI, calculated from height and weight). We estimated associations between COVID-19 status and symptoms reported in March 2021 using log-binomial regression models with heteroscedasticity consistent (robust) standard errors. Associations were reported as excess risk (risk differences, RD) and relative risks (RR). RRs were reported with 95% confidence intervals (CI). We examined associations with unadjusted and adjusted regression models including age and chronic disease. We also examined associations after adjustment for education, BMI and smoking in addition to age and chronic illness. We performed analyses stratified by timing of infection (Wave 1 or 2) while excluding case subjects reporting symptom duration exceeding the time since infection. Controls were included based on recency of . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint reported symptoms and excluded if they reported symptoms with duration >12 months when compared with cases in Wave-1 or >6 months when compared with cases in Wave-2. We also performed analyses stratified by self-reported severity of symptoms and gender, using any COVID-19 diagnosis before February 1 st 2021 as exposure. We examined bivariate correlations between symptoms using tetrachoric correlations, assuming an underlying bivariate normal distribution of the symptoms. Significance of correlations were indicated by a correlation test inferring Pearson correlation with α=0.05. Symptom patterns among all COVID-19 cases were derived from exploratory factor analysis using the tetrachoric correlation matrix. To decide the number of factors, we used Horn's Parallel Analysis for factor retention (Supplementary Figure 1 ). We examined both the two-factor and three-factor solutions, Supplementary Table 2 . We also explored both direct oblimin (oblique, allowing correlated factors) and varimax (orthogonal) rotations. The two underlying factors identified were similar in the two rotation approaches (Table 5 and Supplementary Table 3 ). We omitted rare occurrences (myocarditis, kidney disease) from the factor analysis, as well as symptoms with no increased risk (based on RR) among COVID-19 cases 11-12 months after infection (sleep problems, depression, mood swings, joint pain, muscle pain, hair loss, and fever). Statistical analyses were done in R, version 4.1.0, using packages tidyverse, sandwich, nFactor, polychor, cor.mtest, corrplot, psych. The proportion of missing values in covariates was 11.5% for chronic illness and 3.7% for education level. We performed multiple imputation by chained equations with 20 imputations, using the R package mice. The dataset used for imputation included the following variables: chronic illness, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint In total, 774 (1.0%) of the 73,727 included cohort participants were infected with SARS-CoV-2 in the study period. Figure 2 shows the number of infected MoBa participants per month. Of these, 170 were infected in March or April 2020 (defined as Wave-1 subjects), and 583 participants infected from September 2020 to January 2021 (Wave-2 subjects). All infected and non-infected participants constitute the study population (Table 1) . After 11-12 months, infected subjects had increased risk of 13 of the 22 symptoms when compared to uninfected subjects, with adjusted RRs ranging from 1.8 to 51.4 ( Table 2 ). The symptom with highest excess risk (16.6%) 11-12 months after infection was altered smell or taste. The excess risk for this symptom is not much different from the absolute risk, since only 0.3% of the uninfected subjects reported this as a new symptom. This translates to a large adjusted relative risk (51.4, 95% CI: 36.0-73.5). Other symptoms with relatively high excess risks are poor memory (14.6%) and fatigue (13.6%). Psychological symptoms, such as anxiety, depression and mood swings have low excess risk, which is also the case for fever, muscle and joint pain. Reduced lung function (7.4%) and shortness-of breath (9.9%) have higher excess risk, and the adjusted relative risk of experiencing reduced lung function during the past year is as high as 24.9 (95% CI: 14.6-42.7), since very few (0.3%) uninfected subjects report this as a new symptom. The adjusted relative risk for chest pain was lower in complete case analysis (RR 4.2, 95% CI: 1.5-8.9) than in the imputed data analysis (RR 6.7, 95% CI: 3.6-12.7). Other symptoms showed no large changes in complete cases analysis. Relative risks showed no large changes after adjustment for education, BMI, and smoking in addition to age and prior chronic disease (Supplementary Table 4 ). The picture is much the same after 1-6 months ( Table 3 ). The excess risk for altered smell or taste is 21.8%, while it is 11.7% for poor memory, 17.4% for fatigue and 14.2% for shortness-of-breath. Headache (excess risk 8.9%), dizziness (8.0%), muscle or joint pain (both 4.9%) appear to be relatively more common after 1-6 months compared to 11-12 months. Anxiety and depression have low excess risk also after 1-6 months. The participants were asked whether they had been almost not ill, moderately ill, very ill or hospitalized during the initial infection with SARS-CoV-2. In Table 4 we include all subjects with . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 18, 2021. ; https://doi.org/10.1101/2021.10.15.21265038 doi: medRxiv preprint COVID-19 (wave 1 and 2 and the few subjects infected between the waves) and compare subjects who reported almost no illness (mild illness) with subjects reporting more severe illness (moderately, very ill, or hospitalized). In general, the prevalence of symptoms is about twice as high for subjects with severe infection. For brain fog, the prevalence is 18.1% for severely ill and 9.2% for mildly ill subjects. For shortness-of-breath the proportions are 19.5% and 6.9%, while the figures for altered smell or taste are 23.5% and 16.0%, respectively. Women who have been infected by SARS-CoV-2 report higher prevalence of heart palpitations than infected men (14.1% vs 4.9%) (Supplementary Table 5 ). The relative risk is 2.9 (95% CI: 1.6, 5.5) adjusted for age, prior chronic disease, and severity of infection. They also report higher prevalence of brain fog, fatigue, headache, dizziness, poor memory and altered smell or taste. The proportion of Wave-1 subjects who have no symptoms after 11-12 months is 44%, while it is 38% for Wave-2 subjects after 1-6 months. Among uninfected subjects, the proportion without new symptoms during the last 12 months is 79% (Supplementary Table 6 ). Reporting more than 4 different symptoms was uncommon after both wave 1 and 2. Figure 3 shows bivariate correlations between the symptoms that are significantly associated to sequelae after COVID-19, for Wave-1 (left part) and Wave-2 subjects (right part). Altered smell or taste was weakly correlated with other symptoms. All other symptoms display one or more significant correlations with other symptoms, and the two figures suggest a similar pattern of symptoms for both waves. Using the correlation matrix from both Wave-1 and Wave-2 together (Supplementary Figure 1 and Supplementary Table 7), we found that two underlying, latent factors explained 33% and 17% (in total 50%) of the variance in symptoms (Table 5 ). The correlation between the two factors was 58%. The symptoms that load highest on the first factor are brain fog, poor memory, dizziness, heart palpitations, and fatigue, while shortness-of breath and cough load highest to the second factor. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 18, 2021. Norway among subjects who have and have not been infected. This allows for measures of association between infection and symptoms, using both risk differences and relative risks. We find that some symptoms were clearly associated to infection with SARS-CoV-2. These symptoms cluster into sets, such as a neurocognitive set (e.g. brain fog, dizziness and poor memory) and a cardiorespiratory set (e.g. shortness-of-breath and cough). Altered smell or taste represent a frequent symptom that is more common in women and more common after severe infection but seems to have relatively low correlation to other symptoms. The findings support the view that long COVID may be more than one syndrome 8, 9 . The excess risks for infected subjects were largest for altered smell or taste, poor memory, fatigue and shortness-of-breath after 11-12 months. The same symptoms had high excess risks after 1-6 months. It is interesting that muscle and joint pain have increased relative risk after 1-6 months, but not after 11-12 months. An important finding is that there is low excess risk for anxiety and depression. Post-illness studies of patients with severe coronavirus infection have found a relatively high prevalence of depression 10 . We found that the risk of depression is higher for subjects who experienced a more severe infection initially compared to mildly infected subjects (adjusted RR 1.7, Table 4 ). The results suggest that anxiety and depression might be more a consequence of the severity of initial disease and the trauma of hospitalisation, rather than a direct consequence of the viral infection itself. A unique feature of infection with SARS-CoV-2 is the change in smell and taste 11 . For many patients, these changes disappear shortly after the acute infection, but for a subgroup they remain. We find that 16.6% of Wave-1 subjects report altered smell or taste one year later. This is in accordance with proportions found across other studies 1-3 . The mechanisms behind this symptom is unknown. It is interesting that the correlations between altered smell or taste and cognitive symptoms in our study are relatively low, compatible with a suggestion that the main mechanism may be a local infection in olfactory epithelial cells 12 , rather than an intracerebral affection. This study has limitations. If we compare the prevalence of symptoms in Wave-1 and Wave-2 subjects, and make inferences about the duration of symptoms, there are important assumptions. One is that the type of coronavirus may have changed over time, so that the infection, at least theoretically, may have different long-term consequences. The other factor is that testing opportunities were more restricted during the spring of 2020 compared to later months, possibly inducing differential selection for Wave-1 and Wave-2 subjects. These limitations will be overcome as is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted October 18, 2021. ; https://doi.org/10.1101/2021.10.15.21265038 doi: medRxiv preprint we continue follow-up in MoBa, since viral sequencing has become prevalent, and the same individuals will be followed. The symptoms in this study are self-reported in questionnaires, which has both advantages and draw-backs. The advantage is that one can ask a large, representative sample simple questions in a design that measures the prevalence, duration and correlational structure of symptoms, as well as the degree of association to prior infection. This type of data provides a supplement to what can be learned from linking population samples to health care registrations, as is done, for instance, in the follow-up of veterans in the US 13 . The draw-back is the lack of detail for each participant. There is a possibility for misclassification for signs or diseases that are not easily recognized by the study participants, like myocarditis and kidney disease, as we did not have objective measurements to complement self-reported data. In future research one can link to patient registries and select random subgroups from population-based cohorts for in-depth clinical investigation, in parallel with clinical follow-up of the more severely affected patients. This will give a fuller picture of the clinical spectrum of long COVID. A next step for large cohorts will be to understand why some infected subjects develop long COVID and others do not, by performing nested case-control studies that utilise biomaterials, including whole-genome genotyping. In conclusion, the present design sheds light on the causal link between infection with SARS-CoV-2 and long-term symptoms and suggest distinct clusters of symptoms due to different effects of the virus. The lack of correlations between symptoms question whether the diverse manifestations after infection with SARS-CoV-2 can be classified as one syndrome. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act. The current sub-study was approved by The Regional Committee for Medical and Health Research Ethics, South East Norway C, no. 127708. The Norwegian Mother, Father and Child Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We are grateful to all the participating families in Norway who take part in this on-going cohort study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The authors declare no competing interests. This work was funded by the Norwegian Research Council's Centres of Excellence Funding Scheme (no. 262700) and by the Norwegian Institute of Public Health (NIPH). . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint . CC-BY-NC 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Post-acute COVID-19 syndrome More than 50 long-term effects of COVID-19: a systematic review and meta-analysis Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa) The Norwegian immunisation register--SYSVAK Long covid could be four different syndromes, review suggests The road to addressing Long Covid Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia High-dimensional characterization of post-acute sequelae of COVID-19 Intensity of red colours indicate increasing negative correlation coefficients, while intensity of blue colours indicates increasing positive correlation coefficients ** for p<.01; * for p<.05)